Launch Leucovorin Calcium - Glenmark Pharmaceuticals Ltd

Code BSE: 532296 NSE:

Glenmark Pharmaceuticals Inc., USA is pleased to announce the upcoming launch1 of Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial. Glenmark’s Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, Leucovorin Calcium for Injection, 350 mg/vial, of Hospira, Inc. [NDA 008107]. Glenmark will begin distribution in December 2025. Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “We are pleased to announce the upcoming launch of Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial, further expanding our portfolio of products within the institutional channel, while also strengthening our commitment to bring to market quality and affordable alternatives for patients.”